DRUG-RESISTANT PULMONARY TUBERCULOSIS IN TAY NINH PROVINCE
Main Article Content
Abstract
Background: Drug-resistant pulmonary tuberculosis remains a major challenge for tuberculosis control because of prolonged treatment, high costs, and the risk of community transmission. In Tay Ninh Province, local data are needed to describe the current situation and provide evidence for program management. Objectives: To describe the situation of patients with drug-resistant pulmonary tuberculosis in Tay Ninh Province. Materials and methods: A retrospective cross-sectional descriptive study was conducted among patients aged ≥18 years who were definitively diagnosed with pulmonary tuberculosis according to the guidelines of the Ministry of Health and had bacteriological confirmation by AFB smear microscopy and/or GeneXpert. Drugresistant pulmonary tuberculosis was determined based on GeneXpert MTB/RIF results and/or drug-resistance testing or drug susceptibility testing recorded in tuberculosis management records, allowing classification of resistance patterns to isoniazid, rifampicin, moxifloxacin and other antituberculosis drugs. Data were compiled in Tay Ninh Province from April 1, 2025 to January 31, 2026. Results: During the study period, 1,471 bacteriologically confirmed pulmonary tuberculosis patients were recorded, including 1,427 drug-susceptible cases and 44 drug-resistant cases, corresponding to a drug-resistant tuberculosis rate of 3.0% (95% CI: 2.2–4.0%). Among patients with drug-resistant tuberculosis, males accounted for 68.2% and females for 31.8%; HIV infection was recorded in 4.5% of cases. According to WHO classification, MDR/RR-TB was the predominant category, accounting for 39 cases (88.6%), followed by pre-XDR-TB with 3 cases (6.8%). XDR-TB and other drug-resistant forms were each recorded in 1 case (2.3%). Conclusion: During the study period, the rate of drugresistant pulmonary tuberculosis in Tay Ninh was 3.0% among bacteriologically confirmed cases. Drug-resistant TB cases primarily fell into the MDR/RR-TB category, while pre-XDR-TB and XDRTB were recorded at low rates.
Keywords
Drug-resistant pulmonary tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Cocco N., Gargioni G., Gilpin C., Gonzalez-Angulo L., Grzemska M., et al. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization. 2019.
3. World Health Organization. Global tuberculosis report 2025. 2025. 1-74. https://www.who.int/publications/i/item/9789240116924.
4. Bộ Y tế. Quyết định về việc ban hành tài liệu chuyên môn Hướng dẫn Chẩn đoán, điều trị và dự phòng bệnh Lao. Quyết định số 162/QĐ-BYT ngày 19 tháng 01 năm 2024. 2024.
5. World Health Organization. Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients. Geneva, Switzerland: WHO, 2016. https://www.who.int/news/item/12-05-2016-rapid-diagnostic-test-and-shorter-cheapertreatment-signal-new-hope-for-multidrug-resistant-tuberculosis-patients
6. Chin K. L., Anibarro L., Sarmiento M. E.,Acosta A. Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection. Tropical medicine and infectious disease. 2023. 8 (2), 89, doi: 10.3390/tropicalmed8020089.
7. Gandhi N. R., Brust J. C.,Shah N. S. A new era for treatment of drug-resistant tuberculosis. The European respiratory journal. 2018. 52 (4), 1801350, doi: 10.1183/13993003.01350-2018.
8. Soodejani M. T., Kazemi M., Moradi B.,Mahmudimanesh M. Distribution of Extensively Drug-resistant Tuberculosis in the World Health Organization Regions of the World During 1990-2019. Mediterr J Infect Microb Antimicrob. 2024. 13 (1), 24167, doi: 10.4274/mjima.galenos.2024.24167.16.
9. Van L. H., Phu P. T., Vinh D. N., Son V. T., Hanh N. T., et al. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study. BMC Infect Dis. 2020. 20 (1), 164, doi: 10.1186/s12879-020-4887-1.
10. Trần Thanh Hùng, Trần Đỗ Hùng, Nguyễn Ngọc Bảo Vi, Lương Thị Mỹ Linh, Nguyễn Thị Minh Ngọc, et al. Đặc điểm kiểu hình kháng thuốc của vi khuẩn lao trên bệnh nhân lao phổi kháng thuốc hàng 1 tại tỉnh Bến Tre. Tạp chí Y học Việt Nam. 2025. 546 (1), 249-253, doi: 10.51298/vmj.v546i1.12541.
11. Somoskovi A., Parsons L. M.,Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2001. 2 (3), 164-168, doi: 10.1186/rr54.
12. Nguyen H. V., Tiemersma E. W., Nguyen H. B., Cobelens F. G., Finlay A., et al. The second national tuberculosis prevalence survey in Vietnam. PLoS One. 2020. 15 (4), e0232142, doi: 10.1371/journal.pone.0232142.
13. McQuaid C. F., Horton K. C., Dean A. S., Knight G. M.,White R. G. The risk of multidrug-or rifampicin-resistance in males versus females with tuberculosis. European Respiratory Journal. 2020. 56 (3), doi: 10.1183/13993003.00626-2020.
14. Trinh Q., Nguyen H., Do T., Nguyen V., Nguyen B., et al. Tuberculosis and HIV co-infection in Vietnam. International Journal of Infectious Diseases. 2016. 46 56-60, doi: 10.1016/j.ijid.2016.03.021.